Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 16/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.39 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23877078 | 0.83 | IKZF2 (0.59) | IKZF2CRBNIKZF1 | |
| SCHEMBL24744480 | 0.75 | IKZF2 (0.50) | IKZF2CRBNIKZF1 | |
| SCHEMBL23423439 | 0.73 | CRBN (0.67) | IKZF2CRBNIKZF1 | |
| SCHEMBL23374633 | 0.73 | CRBN (0.67) | IKZF2CRBNIKZF1 | |
| SCHEMBL26415671 | 0.73 | CRBN (0.67) | IKZF2CRBNIKZF1 | |
| SCHEMBL28895869 | 0.72 | IKZF2 (0.62) | IKZF2CRBNIKZF1 | |
| Hydrochloric Acid SCHEMBL29170744 | 0.69 | CRBN (0.52) | IKZF2CRBNIKZF1 | |
| Hydrochloric Acid SCHEMBL30121179 | 0.69 | CRBN (0.52) | IKZF2CRBNIKZF1 | |
| SCHEMBL24407457 | 0.68 | CRBN (0.64) | IKZF2CRBNIKZF1 | |
| SCHEMBL20936151 | 0.68 | IKZF2 (0.60) | IKZF2CRBNIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | IKZF2 4/4885CRBN 867/4885IKZF1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.